Location Directory

Clinical trials in Indianapolis, Indiana

This page shows live ClinicalTrials.gov search results for Indianapolis, Indiana, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

8611

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Interventions: Assessment of Therapy Complications, Questionnaire Administration; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Enrollment: 25,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 163
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 124 more

Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Interventions: Not listed
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2040
U.S. locations: 136
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 133 more

Conditions: Deep Vein Thrombosis (DVT), Thrombus in the Peripheral Venous Vasculature, Venous Embolism, Thrombus in the Central and Peripheral Circulatory System, Including Saphenous Vein Grafts
Interventions: Aspiration thrombectomy system; Device
Lead sponsor: Argon Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Fort Lauderdale, Florida • Indianapolis, Indiana • Edgewood, Kentucky + 1 more

Conditions: Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Interventions: AMG 436; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 7
States / cities: Irvine, California • Newport Beach, California • Zion, Illinois + 4 more

Conditions: Breast Cancer
Interventions: Positron emission tomography (PET), Trastuzumab, Pertuzumab; Procedure · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more

Conditions: Transthyretin Amyloidosis With Cardiomyopathy
Interventions: Nucresiran, Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 45
States / cities: La Jolla, California • Laguna Hills, California • Stanford, California + 38 more

Conditions: Type 1 Diabetes
Interventions: Denosumab, Placebo; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Duarte, California • Indianapolis, Indiana

Conditions: Moderate-to-Severe Atopic Dermatitis
Interventions: Nemolizumab; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 1,935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 136
States / cities: Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 104 more

Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
Interventions: Carboplatin, Mirvetuximab Soravtansine, Bevacizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 73
States / cities: Birmingham, Alabama • Mobile, Alabama • Irvine, California + 65 more

Conditions: Posterior Fossa Ependymal Tumor
Interventions: Metformin, Planned Surgical Resection, Magnetic Resonance Imaging (MRI), Specimen Collection, MR spectroscopy (MRS); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Year to 39 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET, Diagnostic Imaging, Elevated PSA, Positron Emission Tomography, Prostate Biopsy, Carcinoma of the Prostate
Interventions: 68Ga-PSMA-11; Drug
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 338 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Boca Raton, Florida + 13 more

Conditions: Osteogenesis Imperfecta
Interventions: Setrusumab, Placebo; Biological · Other
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 5 Years to 25 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 19 more

Clinical trials in Indianapolis, Indiana

Filter and sort this location

Live official records

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Product Surveillance Registry

Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Denosumab for Type 1 Diabetes

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

PSMA PET Combined With MRI for the Detection of PCa

Setrusumab vs Placebo for Osteogenesis Imperfecta